Skip to content

Ceres Pharmaceuticals

Active
Public limited companyfounded 197056 yrs activeKortrijksesteenweg 1091, 9051 Gent, BelgiumKBO/BCE: BE 0407.326.754
Summary

Ceres Pharmaceuticals has been active since 1970 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €1.3m and a net result of €2.6m. Equity remains stable across the filed fiscal years (±0.3% per year). Its solvency ranks better than 16% of 6016 sector peers (fiscal year 2025). The computed 12-month bankruptcy probability is 1.3% (low).

Risk analysisWatch ReportCompare
Ceres PharmaceuticalsActiveChecked score 64/100
Risk analysis ReportCompare

Overview

Activity
Wholesale of pharmaceutical and medical goods
NACE 46460NACE 51460
1 site
Size
€14.6mturnover 2025
Staff
17.6 FTE
Equity
€1.3m
Profit
€2.6m
Financial health
64 Healthy Checked score 2025
Bankruptcy chance 12 m
1.3%
Structure
Parent
Ceres Pharma · 100%
Auditor: BV PwC BedrijfsrevisorenAccounts 9 d early1 of 17 deeds read
Why 64- Liquidity: current ratio 1.18, cash €39,350, halved- Equity €1.3m (13.9% of total assets)- 1 change of registered office in 24 months+ Figures for FY 2025 (filed 22-07-2026)Show the evidence

Checked score

Score 2025
64 / 100
Healthy
Probability in this band: 0.55% to 1.5%
Better than 41% of its sector peers (NACE 46, small)
Performance against the sector, not lower risk
Every signal that weighs is under Signals.
Financial strength · tick = 2024
Average
Solvency 39-43
equity 13.9% of total assets
Liquidity 4-59
short-term debt 84.5% · cash 0.4%
Profitability 100+83
return on assets 27.9%
Bankruptcy probability, 12 months
1.3% Low
0%0.5%1.5%4%10%≥ 25%

About 1 in 100 comparable companies go bankrupt within 12 months (an estimate).

Sector median 0.2% (4,373 companies)
Last 24 months 11-2024: 0.2% 12-2024: 0.2%● 0.0% vs 11-2024 01-2025: 0.2%● 0.0% vs 12-2024 02-2025: 0.4%▲ +74.8% vs 01-2025 03-2025: 0.4%● 0.0% vs 02-2025 04-2025: 0.4%▲ +6.5% vs 03-2025 05-2025: 0.5%▲ +20.8% vs 04-2025 06-2025: 0.5%▼ -3.6% vs 05-2025 07-2025: 0.5%▲ +2.1% vs 06-2025 08-2025: 0.1%▼ -78.2% vs 07-2025 09-2025: 0.1%● 0.0% vs 08-2025 10-2025: 0.1%● 0.0% vs 09-2025 11-2025: 0.1%● 0.0% vs 10-2025 12-2025: 0.1%● 0.0% vs 11-2025 01-2026: 0.1%● 0.0% vs 12-2025 02-2026: 0.1%▼ -4.3% vs 01-2026lowest value 03-2026: 0.1%● 0.0% vs 02-2026lowest value 04-2026: 0.1%▲ +2.7% vs 03-2026 05-2026: 0.1%▲ +23.9% vs 04-2026 06-2026: 0.1%▼ -1.4% vs 05-2026 07-2026: 0.1%▼ -2.9% vs 06-2026 08-2026: 1.3%▲ +885% vs 07-2026highest value 09-2026: 1.3%● 0.0% vs 08-2026highest value 10-2026: 1.3%● 0.0% vs 09-2026highest value
  • Liquidity: current ratio 1.18, cash €39,350, halved raises the probability
  • Equity €1.3m (13.9% of total assets) raises the probability
  • 1 change of registered office in 24 months raises the probability
  • Figures for FY 2025 (filed 22-07-2026) lowers the probability
Credit up to €80,000 at 30 days acceptable
Liquidity tight (current ratio 1.18 against 2.54 in 2024; short-term debt: 84.5% and cash: 0.4% of total assets), and 86.1% of the assets are financed with debt.
How it is calculated

The band comes from the bankruptcy probability on a scale of 0 to 100: every 10 points more double the odds of getting through the year without bankruptcy.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Place inside the band: half the bankruptcy probability, half how the company does against its sector peers (NACE 46, small). Better than this share of them on solvency 16%, liquidity 4%, profitability 99%, growth against the median 46%. That is performance, not lower risk; the band itself always comes from the probability.

Bankruptcy probability: model pd-v3.202610021621, computed on 03-10-2026. The model learns from Belgian bankruptcies and reads the registers, the annual accounts and the gazette.

Ceilings: negative or zero equity, a heavy loss, a special KBO legal situation and a missing filing 59 (two missing 44), an ongoing judicial reorganisation or an ending 24. Financial strength does not count in the score.

Credit check for your own amount and term

Show the recommended maximum : and see how the verdict changes with amount, term and advance.

Signals

Six signals. The signal on the left, the evidence on the right.
−lowers risk+raises risk○neutral
raises risk · Liquidity: current ratio 1.18, cash €39,350, halved
In the bankruptcy model this factor raises the probability.
NBB · annual accounts
raises risk · Equity €1.3m (13.9% of total assets)
In the bankruptcy model this factor raises the probability.
NBB · annual accounts
raises risk · 1 change of registered office in 24 months
In the bankruptcy model this factor raises the probability.
Belgian State Gazette
lowers risk · Figures for FY 2025 (filed 22-07-2026)
In the bankruptcy model this factor lowers the probability.
NBB · annual accounts
raises risk · Weak solvency vs sector
Solvency (equity / total assets) is in the sector's weakest quartile: better than 16% of 6016 sector peers (2025).
NBB · sector comparison
Position among 6016 sector peers
Solvency
better than 16%
← weakest strongest →
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 22-07-2026, 9 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
9 d early
2024
1 d early
2023
28 d early
2022
13 d early
2021
11 d early
2020
12 d early
2019
29 d early
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

This company filed its last 7 accounts on average 15 days before the deadline; the sector median for financial year 2024 is 3 days before the deadline, and 39% of the sector filed late.

Checked, nothing found (2)
neutral · The next deadline is still running
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. Usually files around 20 July (5 of the last 5 filed years within 30 days of that day).
Companies Code · seven months
Position in the running window
04-10-2026 today31-12-2026 close31-07-2027 deadline
neutral · No strike-offs in the KBO publications
We found no ex-officio strike-off or cessation. Our series starts in 2021 and has gaps, so this is not a confirmation that there is nothing.
KBO publications · our coverage
  1. Annual accounts filedfiscal year 2025 · full…
  2. Appointment: PwC Bedrijfsrevisoren BV (statutory auditor)Permanent representatives: Wouter Coppens and…
  3. Back to profitnet €2.6m

Key points

  • Positive: Back in profit in 2025after -€99,159 in 2024 €2.6m View
  • Caution: Among the weakest 16% on solvencysector median 45.7% · 6,016 companies 13.9% View
  • Positive: Always filed on timeaccounts within the deadline every year 8 years View
  • Controlled by Ceres Pharmaultimately: Ceres Invest 100% View
  • Active since 1970founded 23-09-1970 56 years View

By topic

Financials

Fiscal year
2025
Turnover
€14.6m
Profit
€2.6m
Solvency
13.9%
Turnover▲ 17.1%
Net result
20182025
Go to Financials

Timeline

Events
13
Since
2017
Next accounts
by 31-07-2027
  1. 22-07-2026Annual accounts filed
  2. 10-03-2026Appointment: PwC Bedrijfsrevisoren BV (statutory auditor)
  3. 31-12-2025Back to profit
Go to Timeline

Company details

Sites
1
Legal form
Public limited company
Activity
Wholesale of pharmaceutical and medical goodsNACE 46460
Founded
23-09-1970
Year ends
31-12
Peppol
Reachable for e-invoices
Go to Company details

Go further with this company

How much credit can you give this customer, and on what term?Credit check What should you check before you do business with this company?Supplier due diligence Is the workforce growing, and do people stay?Employer check Can you accept this company as a client under the anti-money-laundering law?AML client file Which of your other customers can you e-invoice via Peppol?Peppol check Which other companies belong to the same group?Ceres Invest · 12 companies

Your own company? See how customers, suppliers and banks see it and what to improve first.

Investigating this company? Keep it with today's facts in a case file.

We would like to set cookies. That happens only with your consent. What we measure